The global economic burden of asthma and chronic obstructive pulmonary disease
- PMID: 26688525
- DOI: 10.5588/ijtld.15.0472
The global economic burden of asthma and chronic obstructive pulmonary disease
Abstract
Non-communicable diseases are now the number one cause of disabilities and loss of life expectancy. Among them, chronic respiratory conditions constitute a major class. The burden of chronic respiratory diseases is generally increasing across the globe, and asthma and chronic obstructive pulmonary disease (COPD) are among the main causes of mortality and morbidity. However, the direct and indirect costs of these conditions vary across jurisdictions. This article reports on recent estimates of the costs of asthma and COPD, with a focus on comparing disease burden across different regions. Overall, there is tremendous variation in per capita annual costs of asthma and COPD. However, the methodology of the cost-of-illness studies is also vastly different, making it difficult to associate differences in reported costs to differences in the true burden of asthma and COPD. Suggestions are provided towards improving the validity and comparability of future studies.
Similar articles
-
History of Asthma in Patients with Chronic Obstructive Pulmonary Disease. A Comparative Study of Economic Burden.Ann Am Thorac Soc. 2016 Feb;13(2):188-96. doi: 10.1513/AnnalsATS.201508-507OC. Ann Am Thorac Soc. 2016. PMID: 26599154
-
The burden of asthma and chronic obstructive pulmonary disease: data from The Netherlands.Pharmacoeconomics. 2001;19 Suppl 2:1-6. doi: 10.2165/00019053-200119002-00001. Pharmacoeconomics. 2001. PMID: 11700783
-
The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991.Respir Med. 2000 Mar;94(3):247-55. doi: 10.1053/rmed.1999.0733. Respir Med. 2000. PMID: 10783936
-
[Pharmaco-economics of asthma and chronic obstructive lung disease].Pol Merkur Lekarski. 2003 Jun;14(84):676-8. Pol Merkur Lekarski. 2003. PMID: 14524302 Review. Polish.
-
Epidemiology, clinical and economic burden, and natural history of chronic obstructive pulmonary disease and asthma.Am J Manag Care. 2004 Jul;10(5 Suppl):S129-38. Am J Manag Care. 2004. PMID: 15354678 Review.
Cited by
-
Revealing the Mechanisms of Qilongtian Capsules in the Treatment of Chronic Obstructive Pulmonary Disease Based on Integrated Network Pharmacology, Molecular Docking, and In Vivo Experiments.ACS Omega. 2024 Jul 18;9(30):32455-32468. doi: 10.1021/acsomega.3c10163. eCollection 2024 Jul 30. ACS Omega. 2024. PMID: 39100362 Free PMC article.
-
Chronic respiratory disease observatory for Africa (CHEST-Africa): study protocol for the prevalence, determinants and economic impacts of asthma and COPD in Africa.BMJ Open Respir Res. 2024 Jul 17;11(1):e002416. doi: 10.1136/bmjresp-2024-002416. BMJ Open Respir Res. 2024. PMID: 39019625 Free PMC article.
-
Anti-Inflammatory Potential of the Anti-Diabetic Drug Metformin in the Prevention of Inflammatory Complications and Infectious Diseases Including COVID-19: A Narrative Review.Int J Mol Sci. 2024 May 10;25(10):5190. doi: 10.3390/ijms25105190. Int J Mol Sci. 2024. PMID: 38791227 Free PMC article. Review.
-
Long-term outcomes in patients with COPD treated with non-invasive ventilation for acute hypercapnic respiratory failure.Ir J Med Sci. 2024 Oct;193(5):2413-2418. doi: 10.1007/s11845-024-03690-w. Epub 2024 May 15. Ir J Med Sci. 2024. PMID: 38744793 Free PMC article.
-
Tele-Monitoring Applications in Respiratory Allergy.J Clin Med. 2024 Feb 4;13(3):898. doi: 10.3390/jcm13030898. J Clin Med. 2024. PMID: 38337592 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical

